R21 in Matrix- M adjuvant vaccine for malaria, falciparum

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Jul 2018: Trial registered, NCT03580824
  2. 30 Apr 2019: Trial started, NCT03580824

The trials

NCT03580824: A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

State
Completed
Phase
Phase 1 and Phase 2
People
91 taking part
Started
30 Apr 2019
Primary completion
14 Jun 2022
Arms
Group 1, Group 2, Group 3
Results
None posted
  1. 9 Jul 2018: Trial registered
  2. 30 Apr 2019: Trial started
  3. 14 Jun 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.